Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening (Oncotarget (2015) 6 (32868-32877) DOI: 10.18632/oncotarget.5210)

Stefano Sestini, Mattia Boeri, Alfonso Marchiano, Giuseppe Pelosi, Carlotta Galeone, Carla Verri, Paola Suatoni, Nicola Sverzellati, Carlo La Vecchia, Gabriella Sozzi, Ugo Pastorino

Research output: Contribution to journalComment/debate

Abstract

This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows: A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.

Original languageEnglish
Number of pages1
JournalOncotarget
Volume10
Issue number57
Publication statusPublished - Oct 1 2019

Fingerprint

MicroRNAs
Lung Neoplasms
Arm
Tomography
Biopsy
Thorax
X-Rays
Lung
Mortality
Neoplasms
Medical Overuse

ASJC Scopus subject areas

  • Oncology

Cite this

Correction : Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening (Oncotarget (2015) 6 (32868-32877) DOI: 10.18632/oncotarget.5210). / Sestini, Stefano; Boeri, Mattia; Marchiano, Alfonso; Pelosi, Giuseppe; Galeone, Carlotta; Verri, Carla; Suatoni, Paola; Sverzellati, Nicola; La Vecchia, Carlo; Sozzi, Gabriella; Pastorino, Ugo.

In: Oncotarget, Vol. 10, No. 57, 01.10.2019.

Research output: Contribution to journalComment/debate

@article{e19d662ba8854e78b9ab34fc7bfd8418,
title = "Correction: Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening (Oncotarget (2015) 6 (32868-32877) DOI: 10.18632/oncotarget.5210)",
abstract = "This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows: A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4{\%} and an overdiagnosis global rate of 18.5{\%}, reaching 78.9{\%} for indolent cancers in the LDCT arm.",
author = "Stefano Sestini and Mattia Boeri and Alfonso Marchiano and Giuseppe Pelosi and Carlotta Galeone and Carla Verri and Paola Suatoni and Nicola Sverzellati and {La Vecchia}, Carlo and Gabriella Sozzi and Ugo Pastorino",
year = "2019",
month = "10",
day = "1",
language = "English",
volume = "10",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "57",

}

TY - JOUR

T1 - Correction

T2 - Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening (Oncotarget (2015) 6 (32868-32877) DOI: 10.18632/oncotarget.5210)

AU - Sestini, Stefano

AU - Boeri, Mattia

AU - Marchiano, Alfonso

AU - Pelosi, Giuseppe

AU - Galeone, Carlotta

AU - Verri, Carla

AU - Suatoni, Paola

AU - Sverzellati, Nicola

AU - La Vecchia, Carlo

AU - Sozzi, Gabriella

AU - Pastorino, Ugo

PY - 2019/10/1

Y1 - 2019/10/1

N2 - This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows: A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.

AB - This article has been corrected: In the Introduction section, the second sentence of the second paragraph was worded incorrectly. The proper sentence is as follows: A significant reduction in lung cancer mortality was reported among the subjects enrolled in the LDCT arm of the National Lung Screening Trial (NLST) when compared to the chest X-ray arm, along with a false discovery rate of 96.4% and an overdiagnosis global rate of 18.5%, reaching 78.9% for indolent cancers in the LDCT arm.

UR - http://www.scopus.com/inward/record.url?scp=85073779827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073779827&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:85073779827

VL - 10

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 57

ER -